IS8481A - Tetrasólafleiður og aðferðir til að meðhöndla efnaskiptatengda sjúkdóma sem þeim tengjast - Google Patents

Tetrasólafleiður og aðferðir til að meðhöndla efnaskiptatengda sjúkdóma sem þeim tengjast

Info

Publication number
IS8481A
IS8481A IS8481A IS8481A IS8481A IS 8481 A IS8481 A IS 8481A IS 8481 A IS8481 A IS 8481A IS 8481 A IS8481 A IS 8481A IS 8481 A IS8481 A IS 8481A
Authority
IS
Iceland
Prior art keywords
methods
disorders associated
metabolic disorders
treating metabolic
tetrazole derivatives
Prior art date
Application number
IS8481A
Other languages
English (en)
Other versions
IS2372B (is
Inventor
Semple Graeme
Schrader Thomas
J. Skinner Philip
L. Colletti Steven
Gharbaoui Tawfik
E. Imbriglio Jason
Jung Jae-Kyu
Liang Rui
Raghavan Subharekha
Schmidt Darby
R. Tata James
Original Assignee
Arena Pharmaceuticals, Inc.
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharmaceuticals, Inc., Merck & Co., Inc. filed Critical Arena Pharmaceuticals, Inc.
Publication of IS8481A publication Critical patent/IS8481A/is
Publication of IS2372B publication Critical patent/IS2372B/is

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IS8481A 2003-10-31 2006-05-24 Tetrasólafleiður og aðferðir til að meðhöndla efnaskiptatengda sjúkdóma sem þeim tengjast IS2372B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51623803P 2003-10-31 2003-10-31
PCT/US2004/035927 WO2005044816A1 (en) 2003-10-31 2004-10-29 Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof

Publications (2)

Publication Number Publication Date
IS8481A true IS8481A (is) 2006-05-24
IS2372B IS2372B (is) 2008-06-15

Family

ID=34572875

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8481A IS2372B (is) 2003-10-31 2006-05-24 Tetrasólafleiður og aðferðir til að meðhöndla efnaskiptatengda sjúkdóma sem þeim tengjast

Country Status (38)

Country Link
US (2) US8637555B2 (is)
EP (2) EP1599469B1 (is)
JP (2) JP4533898B2 (is)
KR (1) KR100850591B1 (is)
CN (1) CN1867562B (is)
AR (1) AR046611A1 (is)
AT (1) ATE328880T1 (is)
AU (1) AU2004287861B2 (is)
BR (1) BRPI0415631A (is)
CA (1) CA2539985C (is)
CO (1) CO5690551A2 (is)
CR (1) CR8270A (is)
CY (1) CY1105479T1 (is)
DE (1) DE602004001134T2 (is)
DK (1) DK1599469T3 (is)
EA (1) EA011484B1 (is)
EC (1) ECSP066529A (is)
ES (1) ES2267077T3 (is)
GE (1) GEP20094801B (is)
HK (1) HK1076468A1 (is)
HR (1) HRP20060286T3 (is)
IL (1) IL174042A0 (is)
IS (1) IS2372B (is)
MA (1) MA28171A1 (is)
MX (1) MXPA06004556A (is)
MY (1) MY140410A (is)
NO (1) NO20062509L (is)
NZ (1) NZ546285A (is)
PE (1) PE20050483A1 (is)
PL (1) PL1599469T3 (is)
PT (1) PT1599469E (is)
RS (1) RS20060290A (is)
SI (1) SI1599469T1 (is)
TN (1) TNSN06150A1 (is)
TW (1) TWI258478B (is)
UA (1) UA86783C2 (is)
WO (1) WO2005044816A1 (is)
ZA (2) ZA200603419B (is)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI258478B (en) 2003-10-31 2006-07-21 Arena Pharm Inc Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
AU2004293415A1 (en) 2003-11-21 2005-06-09 Arena Pharmaceuticals, Inc. 4-oxo-4,5-dihydro-furan-2-carboxylic and acid derivatives and methods of treatment of metabolic-related disorders thereof
WO2006026273A2 (en) * 2004-08-25 2006-03-09 Merck & Co., Inc. Method of treating atherosclerosis, dyslipidemias and related conditions
WO2006052569A1 (en) * 2004-11-05 2006-05-18 Arena Pharmaceuticals, Inc. Compositions for treating flushing and lipid-associated disorders comprising niacin receptor partial agonists
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
US8168799B2 (en) 2005-04-28 2012-05-01 Merck Sharpe & Dohme Ltd. Process for the preparation of tetrazolytetrahydrocyclopentapyrazoles
MX2008000113A (es) 2005-06-28 2008-03-18 Merck & Co Inc Agonistas del receptor de niacina, composiciones que contienen tales compuestos y procedimientos para tratamiento.
DE102006021733A1 (de) * 2006-05-09 2007-11-22 Bayer Healthcare Ag 3-Tetrazolylindazole und 3-Tetrazolylpyrazolopyridine sowie ihre Verwendung
DE102006043443A1 (de) 2006-09-15 2008-03-27 Bayer Healthcare Ag Neue aza-bicyclische Verbindungen und ihre Verwendung
DE102008063992A1 (de) 2008-12-19 2010-09-02 Lerner, Zinoviy, Dipl.-Ing. Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
CN104780915A (zh) 2012-07-11 2015-07-15 埃尔舍利克斯治疗公司 包含他汀、双胍和用于减小心脏代谢风险的其它药剂的组合物
CA2901636A1 (en) 2013-02-21 2014-08-28 Adverio Pharma Gmbh Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate
US9975910B2 (en) 2013-07-23 2018-05-22 Eisai R&D Management Co., Ltd. Hetero-fused cyclic compound
CN103755637A (zh) * 2013-12-26 2014-04-30 平湖优康药物研发有限公司 一种医药中间体1,4,5,6-四氢-3-环戊并吡唑甲腈的合成工艺
US12086719B2 (en) * 2019-10-11 2024-09-10 Royal Bank Of Canada System and method of machine learning using embedding networks

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02178263A (ja) * 1988-12-27 1990-07-11 Kaken Pharmaceut Co Ltd アザアズレン誘導体、その製造法およびそれを有効成分とする抗アレルギー剤および抗炎症剤
US5134155A (en) * 1991-08-08 1992-07-28 Ortho Pharmaceutical Corporation Tetrahydroindazole, tetrahydrocyclopentapyrazole, and hexahydrocycloheptapyrazole compounds and their use as HMG-coA reductase inhibitors
US5948786A (en) 1996-04-12 1999-09-07 Sumitomo Pharmaceuticals Company, Limited Piperidinylpyrimidine derivatives
AU730224B2 (en) 1996-12-23 2001-03-01 Du Pont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
DE69941777D1 (de) 1998-03-10 2010-01-21 Ono Pharmaceutical Co Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
CA2402174A1 (en) 2000-03-09 2001-09-13 Ono Pharmaceutical Co., Ltd. Indole derivatives, process for preparation of the same and use thereof
US20010047027A1 (en) 2000-04-12 2001-11-29 Marc Labelle Prostaglandin D2 receptor antagonists
MXPA02012795A (es) 2000-06-28 2004-07-30 Teva Pharma Carvedilol.
CZ299561B6 (cs) 2000-06-30 2008-09-03 Glaxo Group Limited Chinazolinaminový derivát a farmaceutický prostredek
US6410583B1 (en) 2000-07-25 2002-06-25 Merck Frosst Canada & Co. Cyclopentanoindoles, compositions containing such compounds and methods of treatment
DE10057751A1 (de) 2000-11-22 2002-05-23 Bayer Ag Neue Carbamat-substituierte Pyrazolopyridinderivate
DE60215000T2 (de) 2001-05-23 2007-08-09 Merck Frosst Canada & Co, Kirkland Dihydropyrroloil[1,2-a]indol- und Tetrahydropyridol[1,2-a]indol-Derivate als Prostaglandin-D2-Rezeptor-Antagonisten
DE60234338D1 (de) 2001-06-01 2009-12-24 Hoffmann La Roche Pyrimidin, triazin und pyrazinderivate als glutamatrezeptoren
CA2451128A1 (en) 2001-06-26 2003-01-09 Bristol-Myers Squibb Company N-heterocyclic inhibitors of tnf-alpha expression
ES2217245T3 (es) 2001-06-27 2004-11-01 Rs Tech Corp. Nuevo catalizador saleno quiral y metodos de obtencion de compuestos quirales a partir de epoxidos racemicos utilizando el nuevo catalizador.
JPWO2003022814A1 (ja) 2001-09-07 2004-12-24 小野薬品工業株式会社 インドール誘導体化合物
DE10148617A1 (de) 2001-09-25 2003-04-24 Schering Ag Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
AR038136A1 (es) 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
WO2003078409A1 (fr) 2002-03-19 2003-09-25 Ono Pharmaceutical Co., Ltd. Composes d'acide carboxylique et medicaments renfermant les composes comme principe actif
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
WO2004033431A2 (en) 2002-10-04 2004-04-22 Arena Pharmaceuticals, Inc. Hydroxypyrazoles for use against metabolic-related disorders
ATE429915T1 (de) * 2002-10-10 2009-05-15 Arena Pharm Inc 5-substituierte 2h-pyrazon-3-carbonsäure-derivate als antilipolytische mittel zur behandlung von stoffwechselstörungen, wie z.b. dyslipidemie
DE10261131A1 (de) 2002-12-20 2004-07-01 Grünenthal GmbH Substituierte 5-Aminomethyl-1H-pyrrol-2-carbonsäureamide
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
AR041089A1 (es) 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
AU2004260636A1 (en) 2003-06-13 2005-02-10 Arena Pharmaceuticals, Inc. 5-substituted 2H-pyrazole-3-carboxylic acid derivatives as agonists for the nicotinic acid receptor RUP25 for the treatment of dyslipidemia and related diseases
GB0319124D0 (en) 2003-08-14 2003-09-17 Smithkline Beecham Corp Chemical compounds
GB0319126D0 (en) 2003-08-14 2003-09-17 Smithkline Beecham Corp Chemical compounds
TWI258478B (en) 2003-10-31 2006-07-21 Arena Pharm Inc Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
US7713982B2 (en) 2004-02-14 2010-05-11 Smithkline Beecham Corporation Xanthines with HM74A receptor activity
WO2006026273A2 (en) 2004-08-25 2006-03-09 Merck & Co., Inc. Method of treating atherosclerosis, dyslipidemias and related conditions
WO2006052569A1 (en) 2004-11-05 2006-05-18 Arena Pharmaceuticals, Inc. Compositions for treating flushing and lipid-associated disorders comprising niacin receptor partial agonists
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
US8168799B2 (en) 2005-04-28 2012-05-01 Merck Sharpe & Dohme Ltd. Process for the preparation of tetrazolytetrahydrocyclopentapyrazoles

Also Published As

Publication number Publication date
MA28171A1 (fr) 2006-09-01
JP2010163448A (ja) 2010-07-29
NO20062509L (no) 2006-06-26
PE20050483A1 (es) 2005-08-25
DE602004001134T2 (de) 2007-04-19
TW200530221A (en) 2005-09-16
AU2004287861B2 (en) 2008-08-14
EP1599469A1 (en) 2005-11-30
DK1599469T3 (da) 2006-10-09
DE602004001134D1 (de) 2006-07-20
UA86783C2 (ru) 2009-05-25
ES2267077T3 (es) 2007-03-01
HRP20060286T3 (en) 2007-03-31
EA200600879A1 (ru) 2006-10-27
RS20060290A (en) 2008-11-28
GEP20094801B (en) 2009-10-26
PT1599469E (pt) 2006-10-31
KR20060073974A (ko) 2006-06-29
CO5690551A2 (es) 2006-10-31
PL1599469T3 (pl) 2006-10-31
ZA200606203B (en) 2007-04-25
NZ546285A (en) 2010-04-30
JP4533898B2 (ja) 2010-09-01
SI1599469T1 (sl) 2006-10-31
JP2007509181A (ja) 2007-04-12
IL174042A0 (en) 2006-08-01
BRPI0415631A (pt) 2006-12-12
MXPA06004556A (es) 2006-07-06
CN1867562A (zh) 2006-11-22
ZA200603419B (en) 2006-10-25
MY140410A (en) 2009-12-31
TNSN06150A1 (en) 2007-11-15
WO2005044816A1 (en) 2005-05-19
EA011484B1 (ru) 2009-04-28
CA2539985A1 (en) 2005-05-19
EP1683794A1 (en) 2006-07-26
US20060217562A1 (en) 2006-09-28
IS2372B (is) 2008-06-15
CR8270A (es) 2006-10-06
AU2004287861A1 (en) 2005-05-19
HK1076468A1 (en) 2006-01-20
CA2539985C (en) 2010-02-16
ATE328880T1 (de) 2006-06-15
EP1599469B1 (en) 2006-06-07
TWI258478B (en) 2006-07-21
US8637555B2 (en) 2014-01-28
US20070072924A1 (en) 2007-03-29
KR100850591B1 (ko) 2008-08-05
CY1105479T1 (el) 2010-07-28
AR046611A1 (es) 2005-12-14
ECSP066529A (es) 2006-10-10
CN1867562B (zh) 2011-07-13

Similar Documents

Publication Publication Date Title
IS8481A (is) Tetrasólafleiður og aðferðir til að meðhöndla efnaskiptatengda sjúkdóma sem þeim tengjast
IL188988A0 (en) Methods for preventing and treating metabolic disorders and new pyrazole-o-glycoside derivatives
NO20032220D0 (no) Löfteverktöy II og fremgangsmåte for anvendelse av samme
EP1959428A4 (en) MUSICAL EDITING DEVICE AND METHOD
EP1959429A4 (en) MUSIC EDITING DEVICE AND MUSIC EDITING PROCEDURE
DK3589081T3 (da) Effektstyringfremgangsmåder og -apparat
EP1755733A4 (en) METHOD AND DEVICES FOR THERMAL TREATMENT
PL1725253T3 (pl) Leki i metody leczenia bólu głowy
GB0822148D0 (en) Methods and apparatus
IL180251A0 (en) Methods and reagents for the treatment of metabolic disorders
IL184047A0 (en) Methods and compositions for treating amyloid-related diseases
IL187480A0 (en) Method and composition for treating inflammatory disorders
EP1883782A4 (en) TOKEN SHARING SYSTEM AND METHOD
DE602005001520D1 (de) Zeiteinstellungssystem und Zeiteinstellungsverfahren
EP1958177A4 (en) PERFUSION PROCESS AND DEVICE
IL179864A0 (en) Compounds and methods for treating seizure and paroxysmal disorders
GB0515160D0 (en) Transaction management apparatus and method
NO20053593D0 (no) Arylalkylkarbamat-derivater, fremgangsmate og anvendelse derav i terapi
EP1738509A4 (en) SYSTEM AND METHOD FOR PROVIDING SESSION
FI20055682A0 (fi) Läpivientiosa sekä menetelmä
DE602005019913D1 (de) Therapeutische pyrazoloä3,4-büpyridine und -indazole
EP1804703A4 (en) CRYO-SURGICAL APPARATUS AND RELATED METHODS
NO20050503D0 (no) Fremgangsmate og anordning
NO20044012D0 (no) Fremgangsmate og et system
EP1809276A4 (en) PROCESSING PROCESS